The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Sensitivity of DCog Short for Early Detection of Neurotoxicity
Timeframe: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Specificity of DCog Short for Early Detection of Neurotoxicity
Timeframe: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Positive Predictive Value (PPV) of DCog Short for Early Detection of Neurotoxicity
Timeframe: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Negative Predictive Value (NPV) of DCog Short for Early Detection of Neurotoxicity
Timeframe: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Raw Accuracy of DCog Short for Early Detection of Neurotoxicity
Timeframe: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.